Diabetes and Neuroaxonal Damage in Parkinson's Disease
暂无分享,去创建一个
Y. Ben-Shlomo | H. Zetterberg | T. Foltynie | H. Morris | S. Gandhi | A. Heslegrave | D. Grosset | C. Girges | N. Vijiaratnam | M. Lawton | D. Athauda | R. Real | Tong Guo | Raquel Real
[1] K. Blennow,et al. Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐Tooth disease , 2020, European journal of neurology.
[2] R. Barker,et al. Combining biomarkers for prognostic modelling of Parkinson’s disease , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[3] T. Foltynie,et al. Insulin resistance and Parkinson’s disease: A new target for disease modification? , 2016, Progress in Neurobiology.
[4] P. Calabresi,et al. Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[5] Y. Ben-Shlomo,et al. The Impact of Type 2 Diabetes in Parkinson's Disease , 2021, medRxiv.
[6] C. Gerloff,et al. Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study) , 2022, Movement disorders : official journal of the Movement Disorder Society.